Professional football players in the NFL are four times more likely to develop and die from ALS than the adult male population, according to new research.
The fatal nerve disease has few treatments. But drug developers are hopeful that genetic technologies and a better understanding of biology will bring new options.
A man with Amyotrophic Lateral Sclerosis (ALS) had the advance of his disease slowed, and even halted altogether, thanks to a new trial that could offer hope to the 12,000 to 15,000 patients who currently suffer from the disease.
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) awarded the third annual Healey Center International Prize for Innovation in ALS to the team responsible for the conception, construction, dissemination, and maintenance of the PRO-ACT database that has enabled the new field of ALS predictive analytics.
A normally fractious U.S. House of Representatives came together to provide money for more research and better access to experimental treatments for people afflicted with ALS.
Everyone will be able to unite safely and social distance while walking a couple of laps around the lovely Tom Brown Park. To participate, register a team by contacting Michelle Decker at mdecker@alsafl.org or 888.257.1717 x130.
Study flips belief that disease starts in the spinal cord
‘We need to repair brain motor neurons for effective strategies’
Scientists identify first gene target to revitalize brain motor neuron
ZZ Biotech, a clinical stage biopharmaceutical company developing the experimental drug 3K3A-APC for some of the biggest unmet needs in stroke, neurodegenerative disease and chronic wound healing, today announced that the first patients have been dosed in a Phase 2 clinical trial evaluating 3K3A-APC for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.